Brief: Lundbeck, Otsuka Announce Topline Results From Two Phase III Trials

H Lundbeck A/S

07/09/2023 10:10

Sept 7 (Reuters) - H Lundbeck A/S  HLUNb.CO :
    * LUNDBECK AND OTSUKA ANNOUNCE TOPLINE RESULTS FROM TWO
PHASE III
TRIALS OF BREXPIPRAZOLE AS COMBINATION THERAPY WITH SERTRALINE
FOR TREATMENT OF POST-TRAUMATIC STRESS DISORDER IN ADULTS
    * FLEXIBLE DOSE PHASE III TRIAL MET ITS PRIMARY ENDPOINT,
WHILE
FIXED DOSE PHASE III TRIAL MISSED ITS PRIMARY ENDPOINT
    * OVERALL, SAFETY AND TOLERABILITY RESULTS WERE CONSISTENT
WITH
PROFILE OF BREXPIPRAZOLE AS OBSERVED IN CLINICAL TRIALS FOR
SCHIZOPHRENIA, AGITATION ASSOCIATED WITH DEMENTIA DUE TO
ALZHEIMER'S DISEASE (AADAD), AND ADJUNCTIVE TREATMENT OF MAJOR
DEPRESSIVE DISORDER (MDD)

Source text for Eikon:  ID:nWkr6NBwCt 
Further company coverage:  HLUNb.CO 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com;))